Pyelonephritis Acute Clinical Trial
Official title:
Personalized Antibiotic Treatment in the Emergency Department: Panther Trial
This pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (PDAD). The primary objectives of this pilot trial are to determine the feasibility and safety of conducting a full-scale multi-center randomized controlled trial.
Following informed consent, patients will be randomized to receive 10 days of cephalexin or PDAD (minimum of 3 days of cephalexin followed by placebo once patient reports 24 hours of symptom resolution). Patients will be evaluated at day 1 in-person, then daily using a mobile cellphone application to assess acute uncomplicated pyelonephritis (AUP) symptoms and quality of life (QOL). Urine samples will be collected at in-person visits at day 1, 3 weeks, and 4 weeks. Study feasibility will be assessed through day 90. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03959163 -
The Validity of the Quick Renal MRI in Pediatric Kidney Disease
|
N/A | |
| Suspended |
NCT05544565 -
3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children
|
Phase 4 | |
| Completed |
NCT04651244 -
Diagnostic Imaging of Acute Pyelonephritis
|
||
| Completed |
NCT03179384 -
Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis
|
Phase 4 | |
| Completed |
NCT04594161 -
Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis
|
N/A | |
| Recruiting |
NCT05597540 -
Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.
|
Phase 3 | |
| Withdrawn |
NCT04700787 -
Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
|
Phase 1 |